Dylan Beynon is the founder of the ketamine-assisted therapy startup Mindbloom. He shares what they’ve learned so far from running nearly 703,000 guided ketamine sessions and how he’s been dealing with a recent Wall Street Journal hit piece attempting to discredit his company.
In this conversation, you can expect to learn:
How 703,000+ ketamine sessions revealed what actually drives healing — their data on why music selection, journaling timing, and the 2-5 minute onset of injectable ketamine dramatically impact outcomes versus clinical IV settings
The hidden war between Big Pharma and psychedelic medicine — how Johnson & Johnson created an 88x more expensive version of ketamine, and why Mindbloom is suing the Wall Street Journal for defamation
Why "super well-being", not just "not sick" should be medicine's goal — the shift from disease management to human flourishing, and how psychedelics can unlock 100x improvements in life quality most people don't realize are possible
The real reason IV ketamine is considered "gold standard" (and why it shouldn't be) — how anesthesiologists accidentally created inferior protocols, why injectable beats IV for therapeutic use
